Literature DB >> 23599641

Clinicopathological features and outcomes of patients with gastric cancer: a single-center experience.

Fatih Selcukbiricik1, Evin Buyukunal, Deniz Tural, Mustafa Ozguroglu, Fuat Demirelli, Suheyla Serdengecti.   

Abstract

AIM: To evaluate the location, histopathology, stages, and treatment of gastric cancer and to conduct survival analysis on prognostic factors.
METHODS: Patients diagnosed with of stomach cancer in our clinic between 2000 and 2011, with follow-up or a treatment decision, were evaluated retrospectively. They were followed up by no treatment, adjuvant therapy, or metastatic therapy. We excluded from the study any patients whose laboratory records lacked the operating parameters. The type of surgery in patients diagnosed with gastric cancer was total gastrectomy, subtotal gastrectomy or palliative surgery. Patients with indications for adjuvant treatment were treated with adjuvant and/or radio-chemotherapy. Prognostic evaluation was made based on the parameters of the patient, tumor and treatment.
RESULTS: In this study, outpatient clinic records of patients with gastric cancer diagnosis were analyzed retrospectively. A total of 796 patients were evaluated (552 male, 244 female). The median age was 58 years (22-90 years). The median follow-up period was 12 mo (1-276 mo), and median survival time was 12 mo (11.5-12.4 mo). Increased T stage and N stage resulted in a decrease in survival. Other prognostic factors related to the disease were positive surgical margins, lymphovascular invasion, perineural invasion, cardio-esophageal settlement, and the levels of tumor markers in metastatic disease. No prognostic significance of the patient's age, sex or tumor histopathology was detected.
CONCLUSION: The prognostic factors identified in all groups and the proposed treatments according to stage should be applied, and innovations in the new targeted therapies should be followed.

Entities:  

Keywords:  Chemotherapy; Gastric carcinoma; New agents; Prognostic factors; Survival; Treatment

Mesh:

Year:  2013        PMID: 23599641      PMCID: PMC3627879          DOI: 10.3748/wjg.v19.i14.2154

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

1.  Prognostic value of combination assays for CEA and CA 19-9 in gastric cancer.

Authors:  Y Ikeda; H Oomori; N Koyanagi; M Mori; T Kamakura; S Minagawa; H Tateishi; K Sugimachi
Journal:  Oncology       Date:  1995 Nov-Dec       Impact factor: 2.935

Review 2.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Authors:  Anna D Wagner; Wilfried Grothe; Johannes Haerting; Gerhard Kleber; Axel Grothey; Wolfgang E Fleig
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

3.  Proximal gastric cancers resected via a transabdominal-only approach. Results and comparisons to distal adenocarcinoma of the stomach.

Authors:  L E Harrison; M S Karpeh; M F Brennan
Journal:  Ann Surg       Date:  1997-06       Impact factor: 12.969

4.  Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer.

Authors:  Jin-Pok Kim; Joo-Ho Lee; Soo-Jin Kim; Hang-Jong Yu; Han-Kwang Yang
Journal:  Gastric Cancer       Date:  1998-03       Impact factor: 7.370

5.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

6.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

Review 7.  Prognostic factors for gastric cancer influencing clinical practice.

Authors:  J D Harrison; J W Fielding
Journal:  World J Surg       Date:  1995 Jul-Aug       Impact factor: 3.352

8.  Long-term survivors of gastric cancer: a California population-based study.

Authors:  Pamela L Kunz; Matthew Gubens; George A Fisher; James M Ford; Daphne Y Lichtensztajn; Christina A Clarke
Journal:  J Clin Oncol       Date:  2012-09-04       Impact factor: 44.544

9.  Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites.

Authors:  J Powell; C C McConkey
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

10.  The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone.

Authors:  Sid P Kerkar; Clinton D Kemp; Austin Duffy; Udai S Kammula; David S Schrump; King F Kwong; Martha Quezado; Barry R Goldspiel; Aradhana Venkatesan; Ann Berger; Melissa Walker; Mary Ann Toomey; Seth M Steinberg; Guiseppe Giaccone; Steven A Rosenberg; Itzhak Avital
Journal:  Trials       Date:  2009-12-23       Impact factor: 2.279

View more
  4 in total

1.  Clinicopathological features and trend changes of gastric carcinoma in Southern China.

Authors:  Jian-Jun Peng; Ping Xiao; Jian-Bo Xu; Wu Song; Bing Liao; Yu-Long He
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

2.  Clinicopathologic and immunohistochemical characteristics of gastric adenocarcinoma with enteroblastic differentiation: a study of 29 cases.

Authors:  Takashi Murakami; Takashi Yao; Hiroyuki Mitomi; Takashi Morimoto; Hiroya Ueyama; Kenshi Matsumoto; Tsuyoshi Saito; Taro Osada; Akihito Nagahara; Sumio Watanabe
Journal:  Gastric Cancer       Date:  2015-04-18       Impact factor: 7.370

3.  Should every region use the same gastric cancer scanning and treatment approaches? let's reconsider: a northeastern turkey example.

Authors:  Albayrak Fatih; Ozturk Yasin; Dursun Hakan; Albayrak Yavuz
Journal:  BMC Gastroenterol       Date:  2016-10-04       Impact factor: 3.067

4.  Nomograms predicting prognosis of patients with pathological stages T1N2-3 and T3N0 gastric cancer.

Authors:  Yu-Fei Wang; Xin Yin; Tian-Yi Fang; Yi-Min Wang; Dao-Xu Zhang; Yao Zhang; Xi-Bo Wang; Hao Wang; Ying-Wei Xue
Journal:  World J Gastrointest Surg       Date:  2022-02-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.